ArticleApplied and environmental microbiology2014
Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach.
Article in Applied and environmental microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 135 citations in OpenAlex.
- Review
- Immunotherapy Treatment of Colorectal Cancer and Lung Metastasis with Genetically Modified Outer Membrane Vesicles Delivering Poly-Neoepitopes in a Mouse Model.Applied biochemistry and biotechnology · 2026Article
- Outer membrane vesicles: Versatile nanocarriers for therapeutic delivery and immune modulation.Acta pharmaceutica Sinica. B · 2026Review
- Bacterial Extracellular Vesicles in Biomedical Research and Clinical Translation.Microbial biotechnology · 2026Review
- Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Capsular polysaccharide-mediated protein loading onto extracellular membrane vesicles ofFrontiers in microbiology · 2026Article
- Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.Extracellular vesicles and circulating nucleic acids · 2026Review
- Outer membrane vesicles as a versatile nanoplatform for advanced vaccine development and immunotherapy.Frontiers in immunology · 2026Review
- Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Violacein-Loaded Outer Membrane Vesicles fromACS biomaterials science & engineering · 2025Article
- Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.Journal of extracellular vesicles · 2025Review
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Extracellular Vesicles From Xylella fastidiosa Carry sRNAs and Genomic Islands, Suggesting Roles in Recipient Cells.Journal of extracellular vesicles · 2025Article
- Development of a Recombinant Outer Membrane Vesicles (OMVs)-Based Vaccine Against Helicobacter pylori Infection in Mice.Journal of extracellular vesicles · 2025Article
- Co-purification of the GroEL chaperone during outer membrane vesicle purification: insights fromMicrobiology (Reading, England) · 2025Article
- RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.Journal of nanobiotechnology · 2025Article
- EngineeredInternational journal of nanomedicine · 2025Article
- Overproduction of β-barrel outer membrane proteins inExtracellular vesicles and circulating nucleic acids · 2025Article
- Investigation on antigen-specific T-cell responses induced by outer membrane vesicles fromFrontiers in immunology · 2025Article
- Intranasal delivery ofHuman vaccines & immunotherapeutics · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outer membrane vesicles (OMVs) are spherical nanoparticles that naturally shed from Gram-negative bacteria. They are rich in immunostimulatory proteins and lipopolysaccharide but do not replicate, which increases their safety profile and renders them attractive vaccine vectors. By packaging foreign polypeptides in OMVs, specific immune responses can be raised toward heterologous antigens in the context of an intrinsic adjuvant. Antigens exposed at the vesicle surface have been suggested to elicit protection superior to that from antigens concealed inside OMVs, but hitherto robust methods for targeting heterologous proteins to the OMV surface have been lacking. We have exploited our previously developed hemoglobin protease (Hbp) autotransporter platform for display of heterologous polypeptides at the OMV surface. One, two, or three of the Mycobacterium tuberculosis antigens ESAT6, Ag85B, and Rv2660c were targeted to the surface of Escherichia coli OMVs upon fusion to Hbp. Furthermore, a hypervesiculating ΔtolR ΔtolA derivative of attenuated Salmonella enterica serovar Typhimurium SL3261 was generated, enabling efficient release and purification of OMVs decorated with multiple heterologous antigens, exemplified by the M. tuberculosis antigens and epitopes from Chlamydia trachomatis major outer membrane protein (MOMP). Also, we showed that delivery of Salmonella OMVs displaying Ag85B to antigen-presenting cells in vitro results in processing and presentation of an epitope that is functionally recognized by Ag85B-specific T cell hybridomas. In conclusion, the Hbp platform mediates efficient display of (multiple) heterologous antigens, individually or combined within one molecule, at the surface of OMVs. Detection of antigen-specific immune responses upon vesicle-mediated delivery demonstrated the potential of our system for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.